VISEN Pharmaceuticals

02561

Company Profile

  • Business description

    VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.

  • Contact

    69 Jiuzhang Road
    Suite 3-108, Floor 3, Building B
    Hengtai Lixiang Chuangxin Tower
    Suzhou
    CHN

    http://www.visenpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    52

Stocks News & Analysis

stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks

Our only 5-star wide moat ASX share

A difficult year but better times ahead.
stocks

Is this still an ASX share to own forever?

Find out how this defensive player has fared after earnings.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,140.5011.000.12%
CAC 407,656.1042.82-0.56%
DAX 4023,625.66144.67-0.61%
Dow JONES (US)45,316.53304.76-0.67%
FTSE 1009,204.9811.89-0.13%
HKSE25,417.98359.471.43%
NASDAQ21,621.7185.98-0.40%
Nikkei 22543,018.75438.481.03%
NZX 50 Index13,223.5390.330.69%
S&P 5006,464.5837.50-0.58%
S&P/ASX 2008,871.208.600.10%
SSE Composite Index3,812.5146.641.24%

Market Movers